Sales & Marketing

American Red Cross scores a win against Johnson & Johnson in a legal battle over the use of one of the healthcare?s most recognizable symbols

FDA takes the opportunity to remind industry what reminder ads are, as promotional material for Shire's Fosrenol is deemed in violation of advertising rules

Marketers and sales reps feel the brunt of faltering Procrit sales as J&J consolidates its biologics divisions.

Consumer advertising might be taking a hit in the media and Congress, but pharma was all smiles at this year's PhAME Awards as the best DTC campaigns took the spotlight

Technology isn't the magic bullet, but it can help you hit your target

The tech-savvy creative team at Concentric Rx has its sales force mixing work and play

Thanks to Dr. Google and Nurse Yahoo, pharma consumers know better than ever how to get exactly what they want

Promotional spending is down as companies rationalize and optimize budgets. But in contrast to big changes on the sales side, marketers are still trying to make the old model work

As companies make headway with Web promotions, their marketers express concerns about how best to benchmark online efforts.

Industry forecasts estimate DTC funding to hit $1.39 billion by 2012 with e-mail and Internet campaigns getting the biggest boost.

Blog entries about branded drugs-both positive and negative-are turning up in online keyword searches. Should pharma be worried?

GSK and Merck won high marks from physicians for their electronic promotions, according to a new study. But do docs really want to skip the live sales calls and go online for info?

GSK, Pfizer, and Merck have jumped on the cell-phone marketing bandwagon, but most of pharma is still tiptoeing around the technology. A new report details how pharma can get consumers to text for health info.

New study ranks the top RX product sites and looks at the consumers who view them

Talk to MDs in their language and build a better brand

What Big Pharma needs to learn-and value-about this rapidly growing US demographic

A new study looks at the movement of thought leaders and medical science liaisons from primarily marketing to other areas of the pharma company. Though the shift might be minor (7 percent since 2002), it might be a sign of things to come.

Now that Apple has opened its iPhone to third-party software developers, healthcare productivity programs are leading the charge. Here?s a preview of one of the frontrunners.

Pharma is still having a hard time earning the confidence of the key opinion elite, as only 56 percent claim they trust the industry.

Johnson & Johnson's biologics division launches a new blog in an effort to release easy-to-digest health information and corporate news.

A Kaiser Foundation study finds that although most Americans look favorably upon pharmaceuticals, they generally think drugs are too expensive and that most of the cost is blown on advertising.

Industry insiders explain how pharma companies are reorganizing their salesforces in the wake of industry-wide layoffs

New research points to the power of a highly educated sales force, supporting the case for a voluntary educational standard

Pharm Exec shines the spotlight on the creative innovators behind the best pharmaceutical ads of 2007

Why Big Pharma can no longer afford to treat patient adherence programs as an afterthought

Defending your brand through search optimization

IAG Research released its top-10 list of most-recalled new pharma ads of 2007. Many familiar faces top the list, including the Nasonex bee, Abe Lincoln, and Dr. Jarvik, but how many of those faces will still be there next year?

Avenue A|Razorfish's new digital-outlook report indicates that pharma is still floundering online. Though some pharma companies are taking steps to make their online presence known, others are still crawling.

Under pressure from Congress and public scrutiny, Pfizer voluntarily pulled its controversial television campaign for Lipitor featuring Dr. Jarvik.

Pfizer's consumer ads for Lipitor are causing a stir on the blogs and in Congress. Did the company cross the line by using a famous (but unlicensed) doctor to market a drug, or is this a case of a mistaken identity?